4//SEC Filing
WORLAND STEPHEN T 4
Accession 0001209191-21-053686
CIK 0001828522other
Filed
Aug 26, 8:00 PM ET
Accepted
Aug 27, 5:54 PM ET
Size
26.6 KB
Accession
0001209191-21-053686
Insider Transaction Report
Form 4
WORLAND STEPHEN T
DirectorPresident and Chief Executive
Transactions
- Award
Common Stock
2021-08-25+512,339→ 512,339 total(indirect: By Trust) - Award
Common Stock
2021-08-25+193,141→ 755,480 total - Award
Stock Option (Right to Buy)
2021-08-25+217,284→ 217,284 totalExercise: $0.73Exp: 2024-12-03→ Common Stock (217,284 underlying) - Award
Stock Option (Right to Buy)
2021-08-25+144,856→ 144,856 totalExercise: $1.14Exp: 2026-02-16→ Common Stock (144,856 underlying) - Award
Stock Option (Right to Buy)
2021-08-25+289,712→ 289,712 totalExercise: $1.66Exp: 2027-08-20→ Common Stock (289,712 underlying) - Award
Earn-out Right
2021-08-25+220,639→ 220,639 total→ Common Stock (220,639 underlying) - Award
Common Stock
2021-08-25$10.00/sh+50,000$500,000→ 562,339 total(indirect: By Trust) - Award
Stock Option (Right to Buy)
2021-08-25+619,018→ 619,018 totalExercise: $1.14Exp: 2026-01-07→ Common Stock (619,018 underlying) - Award
Stock Option (Right to Buy)
2021-08-25+33,799→ 33,799 totalExercise: $0.52Exp: 2023-12-16→ Common Stock (33,799 underlying) - Award
Earn-out Right
2021-08-25+75,472→ 75,472 total(indirect: By Trust)→ Common Stock (75,472 underlying)
Footnotes (8)
- [F1]On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Old eFFECTOR was automatically cancelled and converted into approximately 0.09657 (the "Exchange Ratio") shares of common stock of the Issuer.
- [F2]At the Effective Time, each outstanding option to purchase shares of old eFFECTOR common stock (each an "old eFFECTOR Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of old eFFECTOR common stock subject to the applicable old eFFECTOR Option multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share.
- [F3]The stock option vests 25% on December 17, 2014, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
- [F4]The stock option vests 25% on December 4, 2015, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
- [F5]The stock option vests 25% on January 8, 2017, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
- [F6]The stock option vests 25% on February 17, 2017, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
- [F7]The stock option vests 25% on August 21, 2018, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
- [F8]Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an "Earn-Out" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023.
Documents
Issuer
eFFECTOR Therapeutics, Inc.
CIK 0001828522
Entity typeother
Related Parties
1- filerCIK 0001283307
Filing Metadata
- Form type
- 4
- Filed
- Aug 26, 8:00 PM ET
- Accepted
- Aug 27, 5:54 PM ET
- Size
- 26.6 KB